메뉴 건너뛰기




Volumn 38, Issue 5, 2013, Pages 394-400

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization

Author keywords

healthy volunteer; levofloxacin; Monte Carlo simulation; pharmacodynamics; pharmacokinetics

Indexed keywords

LEVOFLOXACIN; PLACEBO;

EID: 84883556137     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12074     Document Type: Article
Times cited : (21)

References (22)
  • 1
    • 84883555597 scopus 로고    scopus 로고
    • Wang F. Zhang Y. eds. Beijing: People's Medical Publishing House
    • Wang F, Zhang Y, eds. Practical antimicrobial therapeutics. Beijing: People's Medical Publishing House, 2004.
    • (2004) Practical Antimicrobial Therapeutics
  • 2
    • 70350776530 scopus 로고    scopus 로고
    • Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia
    • Friedman H, Song X, Crespi S, Navaratnam P,. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia. Value Health, 2009; 12: 1135-1143.
    • (2009) Value Health , vol.12 , pp. 1135-1143
    • Friedman, H.1    Song, X.2    Crespi, S.3    Navaratnam, P.4
  • 3
    • 67649354667 scopus 로고    scopus 로고
    • Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study
    • Frei CR, Jaso TC, Mortensen EM, et al,. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study. Curr Med Res Opin, 2009; 25: 859-868.
    • (2009) Curr Med Res Opin , vol.25 , pp. 859-868
    • Frei, C.R.1    Jaso, T.C.2    Mortensen, E.M.3
  • 4
    • 41149152915 scopus 로고    scopus 로고
    • A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: Focus on length of stay
    • Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W,. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin, 2008; 24: 895-906.
    • (2008) Curr Med Res Opin , vol.24 , pp. 895-906
    • Schein, J.1    Janagap-Benson, C.2    Grant, R.3    Sikirica, V.4    Doshi, D.5    Olson, W.6
  • 6
    • 0034956120 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers
    • Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J,. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother, 2001; 45: 2122-2125.
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2122-2125
    • Chow, A.T.1    Fowler, C.2    Williams, R.R.3    Morgan, N.4    Kaminski, S.5    Natarajan, J.6
  • 7
    • 77952271412 scopus 로고    scopus 로고
    • Levofloxacin in the treatment of community-acquired pneumonia
    • Noreddin AM, Elkhatib WF,. Levofloxacin in the treatment of community-acquired pneumonia. Expert Rev Anti Infect Ther, 2010; 8: 505-514.
    • (2010) Expert Rev Anti Infect Ther , vol.8 , pp. 505-514
    • Noreddin, A.M.1    Elkhatib, W.F.2
  • 8
    • 40349113718 scopus 로고    scopus 로고
    • Levofloxacin: A review of its use as a high-dose, short-course treatment for bacterial infection
    • Anderson VR, Perry CM,. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs, 2008; 68: 535-565.
    • (2008) Drugs , vol.68 , pp. 535-565
    • Anderson, V.R.1    Perry, C.M.2
  • 10
    • 70350508580 scopus 로고    scopus 로고
    • Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: A prospective multicenter study in China
    • Zhang YY, Huang HH, Ren ZY, et al,. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. J Infect Chemother, 2009; 15: 301-311.
    • (2009) J Infect Chemother , vol.15 , pp. 301-311
    • Zhang, Y.Y.1    Huang, H.H.2    Ren, Z.Y.3
  • 11
    • 70350503434 scopus 로고    scopus 로고
    • Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: Results of a prospective multicenter study in China
    • Zhang J, Xu JF, Liu YB, et al,. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother, 2009; 15: 293-300.
    • (2009) J Infect Chemother , vol.15 , pp. 293-300
    • Zhang, J.1    Xu, J.F.2    Liu, Y.B.3
  • 12
    • 0037229596 scopus 로고    scopus 로고
    • Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team
    • Jones RN, Rubino CM, Bhavnani SM, Ambrose PG,. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother, 2003; 47: 292-296.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 292-296
    • Jones, R.N.1    Rubino, C.M.2    Bhavnani, S.M.3    Ambrose, P.G.4
  • 14
    • 79959220301 scopus 로고    scopus 로고
    • Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults
    • Cook AM, Martin C, Adams VR, Morehead RS,. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother, 2011; 55: 3240-3243.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 3240-3243
    • Cook, A.M.1    Martin, C.2    Adams, V.R.3    Morehead, R.S.4
  • 15
    • 73849139599 scopus 로고    scopus 로고
    • Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children
    • Li F, Nandy P, Chien S, Noel GJ, Tornoe CW,. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother, 2010; 54: 375-379.
    • (2010) Antimicrob Agents Chemother , vol.54 , pp. 375-379
    • Li, F.1    Nandy, P.2    Chien, S.3    Noel, G.J.4    Tornoe, C.W.5
  • 17
    • 0041767551 scopus 로고    scopus 로고
    • Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults
    • Rodvold KA, Danziger LH, Gotfried MH,. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother, 2003; 47: 2450-2457.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 2450-2457
    • Rodvold, K.A.1    Danziger, L.H.2    Gotfried, M.H.3
  • 18
    • 34548115791 scopus 로고    scopus 로고
    • Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: Simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model
    • Odenholt I, Cars O,. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother, 2006; 58: 960-965.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 960-965
    • Odenholt, I.1    Cars, O.2
  • 19
    • 24144484187 scopus 로고    scopus 로고
    • Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation
    • Frei CR, Burgess DS,. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy, 2005; 25: 1161-1167.
    • (2005) Pharmacotherapy , vol.25 , pp. 1161-1167
    • Frei, C.R.1    Burgess, D.S.2
  • 20
    • 9644303233 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects
    • Sprandel KA, Schriever CA, Pendland SL, et al,. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. Antimicrob Agents Chemother, 2004; 48: 4597-4605.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 4597-4605
    • Sprandel, K.A.1    Schriever, C.A.2    Pendland, S.L.3
  • 21
    • 0033755095 scopus 로고    scopus 로고
    • Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae
    • Kays MB, Conklin M,. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae. Pharmacotherapy, 2000; 20: 1310-1317.
    • (2000) Pharmacotherapy , vol.20 , pp. 1310-1317
    • Kays, M.B.1    Conklin, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.